HemaCell develops cell therapeutics centered on the platelet lineage, with a flagship product described as the world's first megakaryocyte injection and a pipeline of platelet injection candidates. The company aims to address blood supply shortages and reduce adverse consequences associated with blood transfusions, while pursuing platelet-derived therapeutics for aging-related indications. HemaCell is advancing multiple clinical trials for its lead program and plans to use recent Series B proceeds to support those trials and pipeline development. Management has signaled plans for a pre-IPO fundraising within the year to build manufacturing bases and expand production capacity. Founder Zhu Fangfang stated the company will continue steady, market- and clinic-driven development and rapidly pursue capital market milestones to enable eventual product launches.

Total raised

$62M

Funding rounds

11

Latest round

Series B

Latest activity

Jun 2026